TTY BIOPHARM Business Summary

TTY Biopharm Co., Ltd. (4105.TWO) operates a diversified specialty pharmaceutical model centered on the development, manufacturing, and global distribution of high-barrier generic and proprietary drugs. The company generates revenue through four primary business segments: Oncology (approximately 40% of revenue), Intensive Care/Anti-Infectives (18%), CDMO/Exports (20%), and Healthcare (3%), with additional income derived from strategic equity investments. Its core competitive advantage lies in its proprietary liposomal and microsphere drug delivery platforms, which support flagship products like Lipo-Dox and Lipo-AB. In the regional market, TTY Biopharm competes directly with Sinphar Pharmaceutical, Synmosa Biopharma, and Standard Chemical & Pharmaceutical. It distinguishes itself by maintaining a dominant share of Taiwan’s oncology market and expanding its international footprint through high-value CDMO services and cell-based influenza vaccine distribution. The company is led by a high-profile executive team that bridges political influence with deep industry expertise. Chairman Chuan Lin, who assumed the role in 2018, is a former Premier of Taiwan and Minister of Finance, providing significant strategic and economic oversight. General Manager (CEO) Sara Hou (Ching-Lan Hou) joined in 2022 from Novartis Oncology, where she served as Asia Market Region Head, bringing decades of multinational pharmaceutical leadership to TTY’s global expansion efforts. The management team is supported by CFO Kuo-Chiang Chang and a board featuring prominent independent directors such as former Deloitte Taiwan Chairman Ming-Ling Hsueh. Major institutional backing is provided by Dawan Technology (9.48%), Fubon Life Insurance, and global asset managers including Vanguard and BlackRock, reflecting a stable and institutionalized shareholder base as of February 2026.